RxDoctor Payments Data

David Jones, MD

Critical Care Medicine · Onancock, VANPI 1194712414

Payments from drug & device makers

$480in general payments, 2019–2025

Across 14 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$126
  • Actelion Pharmaceuticals US, Inc.$124
  • GSK$85
  • Johnson & Johnson$61
  • Medtronic$22
  • SK Life Science, Inc.$18
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$480 in reported general payments places this provider in the 55th percentile of 174 critical care medicine providers in Virginia.

See all critical care medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$62,929
Medicare patients
356
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol233$121,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$108,640
Spiriva RespimatTiotropium Bromide167$107,406
Stiolto RespimatTiotropium Br/Olodaterol Hcl106$62,282
Incruse ElliptaUmeclidinium Bromide117$47,038
EliquisApixaban49$45,054
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$44,702
SymbicortBudesonide/Formoterol Fumarate135$40,232
Arnuity ElliptaFluticasone Furoate104$30,600
Fluticasone-SalmeterolFluticasone Propion/Salmeterol103$18,132
Spiriva HandihalerTiotropium Bromide16$15,262
Albuterol Sulfate HfaAlbuterol Sulfate365$13,908
Advair HfaFluticasone Propion/Salmeterol25$10,850
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$10,571
Fluticasone Propionate HfaFluticasone Propionate32$9,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$85$352,422661 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$14$169,688273 claims
PfizerEliquis$126$45,05449 claims
AstraZenecaSymbicort$18$40,232135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 174 critical care medicine providers in Virginia.

Other critical care medicine in Onancock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →